Drug Profile


Alternative Names: 497115; Eltrombopag olamine; Promacta; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer GlaxoSmithKline; Novartis; Technische Universitat Dresden
  • Class Benzoates; Hydrazines; Pyrazoles; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 16 Jan 2017 Novartis Pharmaceuticals plans a phase II trial for Aplastic anaemia (Combination therapy, In infants, In children, In adolescents) in USA (PO) (NCT03025698)
  • 16 Dec 2016 Novartis Pharmaceuticals plans the phase II SOAR trial for Aplastic anaemia (Combination therapy, Treatment-naive, In children, In adolescents, In adults) in Brazil, France and Spain (PO, Tablet) (NCT02998645)
  • 09 Dec 2016 Scottish Medicines Consortium (SMC) approves eltrombopag for restricted use within NHS Scotland for the treatment of chronic idiopathic thrombocytopenic purpura
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top